Resistance and support
228.76
![](https://www.icicidirect.com/Content/images/graph17.png)
Financials( ₹ in Cr) | Themis Medicare Ltd | Sun Pharmaceuticals Industries Ltd | Cipla Ltd | Divis Laboratories Ltd | Zydus Lifesciences Ltd |
---|---|---|---|---|---|
Price | 228.68 | 1,579.30 | 1,510.40 | 4,570.80 | 1,184.80 |
% Change | -1.76 | -1.20 | -0.19 | -1.43 | 0.39 |
Mcap ₹ Cr | 2,104.77 | 378,926.98 | 121,944.71 | 121,340.57 | 119,218.60 |
Revenue TTM ₹ Cr | 381.76 | 48,496.85 | 15,790.60 | 7,665.00 | 19,547.40 |
Net Profit TTM ₹ Cr | 43.52 | 9,648.44 | 2,513.47 | 1,576.00 | 3,854.40 |
PE TTM | 49.96 | 37.93 | 28.66 | 75.74 | 30.89 |
1 Year Return | 53.54 | 51.13 | 48.56 | 25.57 | 103.71 |
ROCE | 14.99 | 17.20 | 14.76 | 16.27 | 23.94 |
ROE | 13.39 | 16.13 | 10.66 | 12.04 | 20.64 |
Equity Capital: 377.66 Cr FV: 1.00
Period | MF Net Purchase / (sold) | FII Net |
---|---|---|
LAST 1M | 21,424.68 | 50,451.86 |
LAST 3M | 101,404.97 | 51,097.20 |
LAST 6M | 186,293.66 | 40,305.54 |
LAST 12M | 309,547.75 | 87,515.42 |
Date | Action Type | Ratio |
---|---|---|
Jul 12, 2024 | Dividend | 50 |
Oct 10, 2023 | Split | 1:10 |
Sep 01, 2023 | Dividend | 50 |
Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. In Mar.`95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital. Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments. Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary. The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products through the collborators throughout the Russian Federation for trade,tenders and govt.supplies.
Plot No 69 A GIDC Indl Estate, Vapi, Valsad, Gujarat, 396195
Tel | : | 91-260-2421675 |
: | sangameshwar.iyer:themismedicare.com; cfoassist:th | |
Website | : | http://www.themismedicare.com |
Link Intime India Pvt Ltd
AGM Date (Month) | : | Sep |
Face Value Equity Shares | : | 1 |
Market Lot Equity Shares | : | 1 |
BSE Code | : | 530199 |
NSE Code | : | THEMISMED |
Book Closure Date (Month) | : | Sep |
BSE Group | : | B |
ISIN | : | INE083B01024 |
You can buy Themis Medicare Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Themis Medicare Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Jul 16, 2024 03:55 PM the closing price of Themis Medicare Ltd was Rs.228.68.
The latest PE ratio of Themis Medicare Ltd as of Jul 16, 2024 03:55 PM is 49.96
The latest PB ratio of Themis Medicare Ltd as of Jul 16, 2024 03:55 PM is 0.16
The 52-week high of Themis Medicare Ltd share price is Rs. 263.85 while the 52-week low is Rs. 142.00
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 16, 2024 03:55 PM, the market cap of Themis Medicare Ltd stood at Rs. 2,104.77 Cr.